Eat A Banana For Hepatitis B Protection?

October 10, 1997

ROSSLYN, Va., October 14, 1997---Would you rather be stuck with a needle or eat a banana? Biomedical engineers at Cornell University would like you to have that choice when you need a vaccine.

Mark Saltzman, Ph.D., is leading a multidisciplinary team of researchers toward the day when genetically altered, edible plant products form the basis for new vaccines, especially those that prevent sexually transmitted diseases.

Saltzman has received one of six grants that together total more than $5 million for research on technologies to reduce health care costs. The awards were made under a joint program of The Whitaker Foundation and the National Science Foundation entitled Multidisciplinary Research and Education in Cost-Reducing Health Care Technologies. More than $14 million in grants have been made under the program since it began in 1993.

"Oral antigen delivery systems will be important in the next generation of vaccines, particularly for pathogens that enter the body primarily through a mucosal surface, as do most sexually transmitted diseases," Saltzman said.

Vaccines made from animal protein are expensive and time-consuming to produce. Animal proteins must be grown in small laboratory cultures, and, because they are injected directly into the bloodstream, they must be highly purified. All this drives up the cost.

Saltzman wants to lower these costs by concentrating the protein from genetically altered plants into an inexpensive, easy-to-administer pill. This is possible because plants can be grown in large quantities in fields or greenhouses, and oral vaccines do not require the same level of purity as injections.

Once pills are developed, the next step would be to produce plants that contain the right dose of vaccine without further processing. Patients would simply eat a fruit or vegetable.

Saltzman's initial target is sexually transmitted diseases. He has already created the first oral vaccine to protect against chlamydia in mice. Next he will focus on a vaccine pill for hepatitis B, because plant-derived proteins have already been produced for this disease.

The project ties together three established areas of technology: transgenic (genetically altered) plants, in which a human antibody or virus gene is inserted into a plant and allowed to replicate; advanced bioprocessing techniques capable of separating and collecting large quantities of plant protein; and advanced drug delivery systems. In Saltzman's lab, the vaccines are being encapsulated in easily digestible, polymer microspheres.

"All the components are already approved and already part of normal medical care," Saltzman said. "We're just putting them together in a very different way." Saltzman and collaborators Michael Shuler, Ph.D., and Charles Arntzen, Ph.D., hope the research will lead to similar applications for other diseases.

"What we're trying to do is sort of generic. Any immune protein could be put into our delivery system," Saltzman said.

Each year in the United States, 12 million people, including 3 million teenagers, acquire a sexually transmitted disease, and billions of dollars are spent on treatment and prevention. The goal of the joint Whitaker-NSF program is to develop technologies to reduce these and other health care costs. The six new grants under this program are:

Case Western Reserve University, $864,528 from Whitaker
Roger Marchant, Ph.D.
Biosynthetic Surfactants: A Novel Biomimetic Surface to Reduce Intra-Coronary Stent Complications.

Cornell University, $893,597 from NSF
W. Mark Saltzman, Ph.D.
Cost-reducing Protein Production and Delivery Methods for STD Prevention

University of Alabama at Birmingham, $781,553 from Whitaker
Raymond Ideker, M.D., Ph.D.
Catheter Ablation of Cardiac Arrhythmias

University of Kansas Medical Center, $818,133 from NSF
Michael Insana, Ph.D.
New Ultrasonic Techniques for Managing Kidney Disease

University of Utah, $769,328 from Whitaker
Joseph Andrade, Ph.D.
Personal Sensors for the Diagnosis and Management of Metabolic Disorders

University of Wisconsin, $887,270 from NSF
Thomas Grist, M.D.
Reducing Health-Care Costs Using 3D Time-resolved Contrast Enhanced Magnetic Resonance Angiography

Whitaker Foundation

Related Vaccines Articles from Brightsurf:

Comprehensive safety testing of COVID-19 vaccines based on experience with prior vaccines
'The urgent need for COVID-19 vaccines must be balanced with the imperative of ensuring safety and public confidence in vaccines by following the established clinical safety testing protocols throughout vaccine development, including both pre- and post-deployment,' write David M.

Safety of HPV vaccines in males
A new analysis published in the British Journal of Clinical Pharmacology shows that HPV vaccines are safe and well tolerated in the male population, and the side effects that may occur after immunization are similar in both sexes.

Model could improve design of vaccines, immunotherapies
Researchers have discovered a general property for understanding how immune cell receptors sense and respond to microbial signals, which could lead to more effective vaccines for both existing and novel viruses.

Better vaccines are in our blood
Red blood cells don't just shuttle oxygen from our lungs to our organs: they also help the body fight off infections by capturing pathogens in the blood and presenting them to immune cells in the spleen.

Challenges in evaluating SARS-CoV-2 vaccines
With more than 140 SARS-CoV-2 vaccines in development, the race is on for a successful candidate to help prevent COVID-19.

Designing vaccines from artificial proteins
EPFL scientists have developed a new computational approach to create artificial proteins, which showed promising results in vivo as functional vaccines.

Misinformation on vaccines readily available online
Parents researching childhood vaccinations online are likely to encounter significant levels of negative information, researchers at the University of Otago, Wellington, have found.

Battle with the cancer: New avenues from childhood vaccines
A new research from the University of Helsinki showed for the first time how the pre-immunization acquired through common childhood vaccines can be used to enhance therapeutic cancer treatment.

Personalized cancer vaccines
The only therapeutic cancer vaccine available on the market has so far showed very limited efficacy in clinical trials.

Doubts raised about effectiveness of HPV vaccines
A new analysis of the clinical trials of HPV vaccines to prevent cervical cancer raises doubts about the vaccines' effectiveness.

Read More: Vaccines News and Vaccines Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to